Mobile

Study of efficacy and safety of QVA149 compared to standard of care, a combination of fluticasone/salmeterol, in patients with moderate to severe COPD

Update Il y a 4 ans
Reference: EUCTR2012-005102-22

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To demonstrate the superiority of QVA149 27.5/12.5 μg twice a day as compared to fluticasone/salmeterol 250/50 μg twice a day in COPD patients with moderate to severe airflow limitation in terms of standardized FEV1 AUC0-12h at Week 12.

Inclusion criteria

  • COPD patients with moderate to severe airflow limitation

Links